Optimizing Statin Therapy

Slides:



Advertisements
Similar presentations
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Advertisements

Muscle pain with taking statin
Statin Myopathy (AHA/ACC/NHLBI)
The Latest Lipid Guidelines:
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
Statin Selection in the Elderly
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Statin Selection Aimed to Reduce New-Onset DM Risk:
Tailoring Statin Therapy in Women
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Expert Perspectives on Clinically Challenging Cases in Narcolepsy
Challenging Statin Intolerance: Back to Basics
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
American Heart Association Scientific Sessions
Obesity and Dyslipidemia: How Would You Treat?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
What Do We Know About LDL-C?
Understanding Statin Metabolism
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
Diabetes Increases Risk of CVD
Assessing the State of Statin Therapy
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Is it Time for a Paradigm Change in HIV Management?
PrEP.
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.
A Patient Journey Through Statin Intolerance
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Oral Anticoagulation in AF
Statins and HIV:.
New LDL-C Lipid Targets
Exploring Statin Intolerance
Lipid Clinic Challenge
Clinicians' Corner in Dyslipidemia
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Statins, Obesity, and Hyperlipidemia
Glucose Management and Statin Therapy
How to Optimize Cholesterol Management in High-Risk CV Patients
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Reducing Risk for CV Outcomes
A Family Affair.
New Lipid-Lowering Guidelines
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Statins and Glucose Metabolism: An Endocrinology Perspective
Glucose Management and Statin Therapy
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Statin Selection in Patients With Pre-Diabetes: Case Considerations
Statin Therapy in Patients With Insulin Resistance
Lipids, the Heart, and the Kidney
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

Optimizing Statin Therapy

Multiple Challenges in Statin Selection

What Are Your Patients' Needs and Risks What Are Your Patients' Needs and Risks? Pick the Right Statin for Your Patient

Key Points to Get Across to Your Patient

Relationship Between LDL-C Reduction and CHD Relative Risk

Begin a Dialog

Choose the Right Statin Not All Statins Are Created Equal

Statin Pharmacokinetics

Statin Safety in HIV on ART

Intensity of Statin Therapy

Polypharmacy and Drug-Drug Interactions

CYP450

Pitavastatin and Pravastatin Minimal CYP Involvement

Statin-Associated Myopathy Risk Factors

Statin-Associated Myopathy Risk Factors (cont)

Main Message Regarding AEs and Statins

Reassurance

Risk of T2D Lower With Some Statins

The Challenges With Insurance

Lifestyle Modifications

Myth Busters

No Link Between Statins and Dementia Randomized Clinical Trial Evidence

The Nudge Into T2D

Patient Education Team Approach

Abbreviations

Abbreviations (cont)